Your browser is no longer supported. Please, upgrade your browser.
NVTA Invitae Corporation daily Stock Chart
Invitae Corporation
Index- P/E- EPS (ttm)-3.89 Insider Own1.80% Shs Outstand129.02M Perf Week-10.63%
Market Cap7.96B Forward P/E- EPS next Y-1.58 Insider Trans-8.29% Shs Float105.68M Perf Month2.18%
Income-420.50M PEG- EPS next Q-0.66 Inst Own67.80% Short Float20.13% Perf Quarter42.02%
Sales233.20M P/S34.15 EPS this Y-37.40% Inst Trans0.18% Short Ratio7.99 Perf Half Y181.95%
Book/sh3.60 P/B12.23 EPS next Y51.20% ROA-50.50% Target Price41.54 Perf Year160.75%
Cash/sh2.33 P/C18.86 EPS next 5Y8.00% ROE-106.90% 52W Range7.41 - 55.38 Perf YTD173.03%
Dividend- P/FCF- EPS past 5Y-12.30% ROI-34.60% 52W High-20.48% Beta2.12
Dividend %- Quick Ratio3.60 Sales past 5Y166.80% Gross Margin34.70% 52W Low493.93% ATR3.00
Employees1500 Current Ratio3.70 Sales Q/Q-13.60% Oper. Margin- RSI (14)47.66 Volatility5.52% 6.36%
OptionableYes Debt/Eq0.60 EPS Q/Q-140.70% Profit Margin- Rel Volume1.05 Prev Close47.24
ShortableYes LT Debt/Eq0.60 EarningsAug 04 AMC Payout- Avg Volume2.66M Price44.04
Recom2.10 SMA20-6.16% SMA5011.59% SMA20074.57% Volume2,806,746 Change-6.77%
Oct-14-20Downgrade JP Morgan Overweight → Neutral
Sep-09-20Initiated Morgan Stanley Equal-Weight $38
Jul-01-20Downgrade The Benchmark Company Buy → Hold
Aug-07-19Reiterated The Benchmark Company Buy $26 → $28
Mar-04-19Initiated Chardan Capital Markets Buy $29
Dec-19-18Initiated Oppenheimer Outperform
Nov-20-18Resumed The Benchmark Company Buy $17
Feb-13-18Reiterated The Benchmark Company Buy $11 → $10
Jan-16-18Reiterated The Benchmark Company Buy $16 → $11
Jan-16-18Reiterated Leerink Partners Outperform $12 → $10
Jan-05-18Initiated Ladenburg Thalmann Buy $15
Apr-03-17Reiterated The Benchmark Company Buy $11 → $16
Feb-14-17Upgrade The Benchmark Company Hold → Buy $8.50 → $11
Nov-10-16Resumed Leerink Partners Outperform
Jun-30-16Initiated The Benchmark Company Hold $8.50
Jan-28-16Downgrade Leerink Partners Outperform → Mkt Perform
Aug-14-15Initiated William Blair Mkt Perform
May-14-15Upgrade Leerink Partners Mkt Perform → Outperform
Oct-19-20 12:43PM  
Oct-08-20 07:30AM  
Oct-07-20 10:23AM  
Oct-05-20 07:30AM  
Oct-01-20 02:22PM  
Sep-30-20 06:04AM  
Sep-22-20 07:02AM  
Sep-17-20 08:24AM  
Sep-16-20 01:39AM  
Sep-15-20 05:00AM  
Sep-14-20 04:50PM  
Sep-11-20 07:30AM  
Sep-09-20 08:00AM  
Sep-03-20 07:47AM  
Sep-01-20 07:30AM  
Aug-26-20 11:25AM  
Aug-06-20 01:30PM  
Aug-05-20 03:32PM  
Aug-04-20 06:45PM  
Jul-29-20 05:50PM  
Jul-28-20 12:33PM  
Jul-27-20 02:36AM  
Jul-21-20 07:05AM  
Jul-16-20 11:15AM  
Jul-15-20 03:35PM  
Jul-14-20 05:40PM  
Jul-13-20 05:50PM  
Jul-09-20 06:41PM  
Jul-08-20 06:05PM  
Jul-07-20 08:53PM  
Jul-06-20 05:15PM  
Jul-05-20 09:20PM  
Jul-03-20 03:28AM  
Jul-02-20 12:00PM  
Jul-01-20 06:48PM  
Jun-26-20 10:28PM  
Jun-25-20 11:30AM  
Jun-24-20 05:21PM  
Jun-22-20 10:38AM  
Jun-20-20 10:20AM  
Jun-16-20 07:17AM  
Jun-11-20 03:49PM  
Jun-09-20 11:30AM  
Jun-05-20 01:45AM  
Jun-02-20 02:00AM  
May-28-20 03:34PM  
May-21-20 11:30AM  
May-18-20 07:00PM  
May-13-20 04:14AM  
May-08-20 09:00AM  
May-07-20 07:30AM  
May-06-20 12:31PM  
May-05-20 07:05PM  
May-04-20 09:34AM  
Apr-28-20 12:33PM  
Apr-27-20 04:00PM  
Apr-21-20 04:05PM  
Apr-15-20 02:50PM  
Apr-07-20 07:30AM  
Apr-06-20 04:05PM  
Apr-01-20 10:48PM  
Mar-30-20 05:45PM  
Mar-23-20 05:45PM  
Mar-13-20 08:38AM  
Mar-10-20 04:22PM  
Mar-03-20 07:30AM  
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. It offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, metabolic conditions, and rare diseases; prenatal and perinatal genetic tests; and non-invasive prenatal screening products. The company also provides preimplantation and carrier screening for inherited disorders; products for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders; a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, a platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. Invitae Corporation has a collaboration with Gene Therapies Ltd. for the detection of lysosomal storage disorders in children. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stueland KatherineChief Commercial OfficerOct 13Sale51.361,00051,360238,352Oct 15 05:38 PM
Nussbaum Robert LChief Medical OfficerOct 09Option Exercise9.906,55064,845215,211Oct 13 06:18 PM
Stueland KatherineChief Commercial OfficerSep 15Sale35.511,00035,510239,352Sep 16 06:44 PM
WERNER ROBERT F.Chief Accounting OfficerSep 10Sale33.872468,33130,334Sep 14 06:47 PM
George Sean EPresident & CEOSep 10Sale33.8774225,129638,376Sep 14 06:46 PM
Guyer Shelly DChief Financial OfficerSep 10Sale33.8763121,370227,520Sep 14 06:45 PM
Stueland KatherineChief Commercial OfficerSep 10Sale33.8763121,370240,352Sep 14 06:44 PM
Nussbaum Robert LChief Medical OfficerSep 10Sale33.5623,175777,812208,661Sep 14 06:43 PM
Brida ThomasGeneral CounselSep 10Sale33.8763321,438212,252Sep 14 06:41 PM
Stueland KatherineChief Commercial OfficerAug 19Sale32.1021,345685,102239,730Aug 20 05:55 PM
WERNER ROBERT F.Chief Accounting OfficerAug 19Sale32.101,74055,84730,037Aug 20 05:54 PM
Guyer Shelly DChief Financial OfficerAug 19Sale32.1018,956608,417226,898Aug 20 05:53 PM
Brida ThomasGeneral CounselAug 19Sale32.1012,416398,508211,628Aug 20 05:53 PM
George Sean EPresident & CEOAug 19Sale32.1015,473496,629637,643Aug 20 05:51 PM
Nussbaum Robert LChief Medical OfficerAug 19Sale32.1019,049611,399230,730Aug 20 05:50 PM
Stueland KatherineChief Commercial OfficerAug 12Sale29.311,00029,310261,075Aug 13 04:54 PM
Guyer Shelly DChief Financial OfficerJul 17Sale33.1612,000397,927245,854Jul 20 06:35 PM
AGUIAR ERICDirectorJul 15Option Exercise8.0810,00080,80010,000Jul 16 06:50 PM
AGUIAR ERICDirectorJul 15Sale33.9910,000339,8530Jul 16 06:50 PM
Stueland KatherineChief Commercial OfficerJul 14Sale32.501,00032,500262,075Jul 16 06:51 PM
BENDEKGEY E LEEChief Operating OfficerJul 13Option Exercise2.8227,50077,550245,811Jul 15 06:30 AM
BENDEKGEY E LEEChief Operating OfficerJul 13Sale34.1627,500939,509218,311Jul 15 06:30 AM
Nussbaum Robert LChief Medical OfficerJul 09Sale34.1529,7831,017,112249,779Jul 13 05:21 PM
Stueland KatherineChief Commercial OfficerJun 12Sale16.341,00016,340203,925Jun 16 09:13 PM
Nussbaum Robert LChief Medical OfficerJun 03Option Exercise9.9020,000198,000220,412Jun 05 06:45 PM
Nussbaum Robert LChief Medical OfficerMay 22Sale17.2819,893343,763200,412May 22 06:42 PM
Nussbaum Robert LChief Medical OfficerMay 20Sale16.706,864114,634220,305May 22 06:42 PM
Guyer Shelly DChief Financial OfficerMay 20Sale16.705,25087,679198,704May 22 06:02 PM
Stueland KatherineChief Commercial OfficerMay 20Sale16.706,177103,161204,925May 22 06:00 PM
BENDEKGEY E LEEChief Operating OfficerMay 20Sale16.709,348156,119159,161May 22 05:58 PM
Brida ThomasGeneral CounselMay 20Sale16.702,06034,404164,894May 22 05:57 PM
George Sean EPresident & CEOMay 20Sale16.7025,500425,870526,566May 22 05:56 PM
Stueland KatherineChief Commercial OfficerMay 13Sale17.561,00017,560211,102May 14 05:04 PM
BENDEKGEY E LEEChief Operating OfficerMay 12Sale18.1118,665338,079168,509May 14 05:04 PM
Stueland KatherineChief Commercial OfficerApr 13Sale12.801,00012,803212,102Apr 14 06:44 PM
BENDEKGEY E LEEChief Operating OfficerMar 16Sale11.7911,056130,350187,174Mar 16 09:47 PM
Brida ThomasGeneral CounselMar 16Sale11.799,226108,775165,868Mar 16 09:45 PM
George Sean EPresident & CEOMar 16Sale11.7911,655137,412552,066Mar 16 09:42 PM
Nussbaum Robert LChief Medical OfficerMar 16Sale11.7910,684125,964227,169Mar 16 09:40 PM
Guyer Shelly DChief Financial OfficerMar 16Sale11.7910,684125,964203,954Mar 16 09:39 PM
Stueland KatherineChief Commercial OfficerMar 16Sale11.7910,684125,964213,102Mar 16 09:50 PM
Stueland KatherineChief Commercial OfficerMar 13Sale11.641,00011,644223,786Mar 16 09:50 PM
Stueland KatherineChief Commercial OfficerFeb 27Sale20.441,00020,435133,053Mar 02 04:09 PM
BENDEKGEY E LEEChief Operating OfficerFeb 26Option Exercise6.6785,963573,780226,286Feb 28 07:42 PM
BENDEKGEY E LEEChief Operating OfficerFeb 26Sale20.76119,7892,487,087106,497Feb 28 07:42 PM
Stueland KatherineChief Commercial OfficerJan 14Sale18.141,00018,137134,053Jan 15 07:39 PM
Stueland KatherineChief Commercial OfficerDec 13Sale17.081,00017,082135,053Dec 16 06:40 PM
Stueland KatherineChief Commercial OfficerNov 14Sale17.463,78866,123136,053Nov 15 09:42 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.